Am J Clin Nutr:糖酵解/糖异生相关的代谢产物与心血管疾病高风险地中海人群的T2D发病风险密切相关

2020-08-05 MedSci原创 MedSci原创

糖酵解/葡萄糖生成和三羧酸(TCA)循环代谢物与2型糖尿病(T2D)有关。然而,这些代谢物与T2D发病率的关联以及饮食干预的潜在效果仍不清楚。我们旨在评估糖酵解/葡萄糖生成和TCA循环代谢物的基线和1

糖酵解/葡萄糖生成和三羧酸(TCA)循环代谢物与2型糖尿病(T2D)有关。然而,这些代谢物与T2D发病率的关联以及饮食干预的潜在效果仍不清楚。我们旨在评估糖酵解/葡萄糖生成和TCA循环代谢物的基线和1-y变化与胰岛素抵抗和T2D发病率的关联,以及地中海饮食(MedDiet)干预的潜在调节作用。

 

我们在PREDIMED研究中纳入了251例T2D事件病例和638例非病例,在中位随访3.8年期间,参与者被分配到MedDiet+特级初榨橄榄油、MedDiet+坚果或对照饮食。通过LC串联质谱法使用靶向方法测量血浆代谢物。使用加权Cox回归模型并校正潜在混杂因素,测试了基线和1-y糖酵解/葡萄糖生成和TCA循环代谢物的变化与随后T2D风险的关联。我们设计了一个结合所有这些代谢物的加权评分,并应用了留一法交叉验证方法。

 

结果显示,基线血液中的己糖单磷酸、丙酮酸、乳酸、丙氨酸、甘油-3磷酸和异柠檬酸的循环浓度与较高的T2D风险显著相关(每增加1-SD,风险增加17-44%)。每次1-SD升高,包括所有代谢物在内的加权评分与T2D相对危险性增加30%(95%CI:1.12,1.51)相关。基线乳酸和丙氨酸与胰岛素抵抗的稳态模型评估的基线和1-y变化相关。随访1年后,大多数代谢产物和加权评分的一年增加与T2D相对危险性升高相关。MedDiet组的风险低于对照组,尽管在校正多重比较后没有发现显著的相互作用。

 

总之,该研究确定了一组与糖酵解/糖异生相关的代谢产物,这些代谢产物与血管疾病高风险地中海人群的T2D风险密切相关。MedDiet可以抵消这些代谢产物的有害作用。

 

原始出处:

 

Marta Guasch-FerréJosé L Santos, et al., Glycolysis/gluconeogenesis- and tricarboxylic acid cycle-related metabolites, Mediterranean diet, and type 2 diabetes. Am J Clin Nutr. 2020 Apr 1;111(4):835-844. doi: 10.1093/ajcn/nqaa016.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1862133, encodeId=9a1d1862133cd, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sat Sep 19 03:05:38 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664720, encodeId=50571664e2059, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Mon Aug 17 08:05:38 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275781, encodeId=b81712e578134, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498761, encodeId=ee8f1498e6158, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513470, encodeId=f8a715134e047, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575529, encodeId=987115e55297d, content=<a href='/topic/show?id=cd9941326bc' target=_blank style='color:#2F92EE;'>#地中海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41326, encryptionId=cd9941326bc, topicName=地中海)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303116130321, createdName=wgx311, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1862133, encodeId=9a1d1862133cd, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sat Sep 19 03:05:38 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664720, encodeId=50571664e2059, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Mon Aug 17 08:05:38 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275781, encodeId=b81712e578134, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498761, encodeId=ee8f1498e6158, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513470, encodeId=f8a715134e047, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575529, encodeId=987115e55297d, content=<a href='/topic/show?id=cd9941326bc' target=_blank style='color:#2F92EE;'>#地中海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41326, encryptionId=cd9941326bc, topicName=地中海)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303116130321, createdName=wgx311, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1862133, encodeId=9a1d1862133cd, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sat Sep 19 03:05:38 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664720, encodeId=50571664e2059, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Mon Aug 17 08:05:38 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275781, encodeId=b81712e578134, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498761, encodeId=ee8f1498e6158, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513470, encodeId=f8a715134e047, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575529, encodeId=987115e55297d, content=<a href='/topic/show?id=cd9941326bc' target=_blank style='color:#2F92EE;'>#地中海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41326, encryptionId=cd9941326bc, topicName=地中海)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303116130321, createdName=wgx311, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1862133, encodeId=9a1d1862133cd, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sat Sep 19 03:05:38 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664720, encodeId=50571664e2059, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Mon Aug 17 08:05:38 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275781, encodeId=b81712e578134, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498761, encodeId=ee8f1498e6158, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513470, encodeId=f8a715134e047, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575529, encodeId=987115e55297d, content=<a href='/topic/show?id=cd9941326bc' target=_blank style='color:#2F92EE;'>#地中海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41326, encryptionId=cd9941326bc, topicName=地中海)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303116130321, createdName=wgx311, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1862133, encodeId=9a1d1862133cd, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sat Sep 19 03:05:38 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664720, encodeId=50571664e2059, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Mon Aug 17 08:05:38 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275781, encodeId=b81712e578134, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498761, encodeId=ee8f1498e6158, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513470, encodeId=f8a715134e047, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575529, encodeId=987115e55297d, content=<a href='/topic/show?id=cd9941326bc' target=_blank style='color:#2F92EE;'>#地中海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41326, encryptionId=cd9941326bc, topicName=地中海)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303116130321, createdName=wgx311, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1862133, encodeId=9a1d1862133cd, content=<a href='/topic/show?id=a374102813a1' target=_blank style='color:#2F92EE;'>#高风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102813, encryptionId=a374102813a1, topicName=高风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Sat Sep 19 03:05:38 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664720, encodeId=50571664e2059, content=<a href='/topic/show?id=0b27e6816d0' target=_blank style='color:#2F92EE;'>#糖异生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76816, encryptionId=0b27e6816d0, topicName=糖异生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271f25816039, createdName=ms1774076774505970, createdTime=Mon Aug 17 08:05:38 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275781, encodeId=b81712e578134, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498761, encodeId=ee8f1498e6158, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1513470, encodeId=f8a715134e047, content=<a href='/topic/show?id=8e4b2540671' target=_blank style='color:#2F92EE;'>#代谢产物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25406, encryptionId=8e4b2540671, topicName=代谢产物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e1510553828, createdName=124987c6m39暂无昵称, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575529, encodeId=987115e55297d, content=<a href='/topic/show?id=cd9941326bc' target=_blank style='color:#2F92EE;'>#地中海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41326, encryptionId=cd9941326bc, topicName=地中海)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303116130321, createdName=wgx311, createdTime=Fri Aug 07 14:05:38 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
    2020-08-07 wgx311

相关资讯

JAHA:鲁格列净对伴有糖尿病的射血分数正常心衰患者的影响

在伴有2型糖尿病的HFpEF患者中,鲁格列净和伏格列波糖治疗12周后BNP降低的程度没有显著差异。

Circulation:骨髓内皮细胞对糖尿病骨髓造血的调节作用

糖尿病是一个常见公共健康问题,在中国,约有1.1亿糖尿病患者。糖尿病可导致严重的心血管并发症,明显增加冠心病的风险。骨髓造血在糖尿病并发症发生中具有怎样的作用,目前尚不明确。

Eur Heart J:不健康饮食、肥胖、糖尿病和心血管病是致命“四连环”!

近日,欧洲心脏病杂志主编Thomas F Lüscher教授撰文介绍了几项研究,并称不健康饮食、肥胖、糖尿病和心血管病之间有致命性的“四连环”关系。

Cell Meta: 一种口服降糖药治疗糖尿病的效果优于二甲双胍和恩格列净!对30万种化合物高通量筛选得出!

谈及糖尿病降糖药,就会有个疑问,首选二甲双胍,还是恩格列净?今年的欧洲新指南对这二甲双胍和恩格列净等SGLT-2抑制剂进行了重新定位,认为SGLT2抑制剂已经超越了二甲双胍。